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in the Succinate Dehydrogenase Genes
in Cowden and Cowden-like Syndromes
Ying Ni,1,2,3,7 Kevin M. Zbuk,1,2,7 Tammy Sadler,1,2 Attila Patocs,1,2 Glenn Lobo,1,2 Emily Edelman,1,2,4
Petra Platzer,1,2 Mohammed S. Orloff,1,2,4 Kristin A. Waite,1,2,4 and Charis Eng1,2,3,4,5,6,*
Individuals with PTENmutations have Cowden syndrome (CS), associated with breast, thyroid, and endometrial neoplasias. Manymore
patients with features of CS, not meeting diagnostic criteria (termed CS-like), are evaluated by clinicians for CS-related cancer risk. Germ-
line mutations in succinate dehydrogenase subunits SDHB-D cause pheochromocytoma-paraganglioma syndrome. One to ﬁve percent
of SDHB/SDHD mutation carriers have renal cell or papillary thyroid carcinomas, which are also CS-related features. SDHB-D may be
candidate susceptibility genes for some PTENmutation-negative individuals with CS-like cancers. To address this hypothesis, germline
SDHB-D mutation analysis in 375 PTEN mutation-negative CS/CS-like individuals was performed, followed by functional analysis of
identiﬁed SDH mutations/variants. Of 375 PTEN mutation-negative CS/CS-like individuals, 74 (20%) had increased manganese super-
oxide dismutase (MnSOD) expression, a manifestation of mitochondrial dysfunction. Among these, 10 (13.5%) had germline muta-
tions/variants in SDHB (n ¼ 3) or SDHD (7), not found in 700 controls (p < 0.001). Compared to PTEN mutation-positive CS/CS-like
individuals, those with SDH mutations/variants were enriched for carcinomas of the female breast (6/9 SDH versus 30/107 PTEN, p <
0.001), thyroid (5/10 versus 15/106, p < 0.001), and kidney (2/10 versus 4/230, p ¼ 0.026). In the absence of PTEN alteration, CS/
CS-like-related SDHmutations/variants show increased phosphorylation of AKTand/orMAPK, downstreammanifestations of PTEN dys-
function. Germline SDHmutations/variants occur in a subset of PTENmutation-negative CS/CS-like individuals and are associated with
increased frequencies of breast, thyroid, and renal cancers beyond those conferred by germline PTENmutations. SDH testing should be
considered for germline PTENmutation-negative CS/CS-like individuals, especially in the setting of breast, thyroid, and/or renal cancers.Introduction
Phosphatase and tensin homolog deleted on chromosome
ten (PTEN [MIM 601728]) is a ubiquitous tumor suppressor
that plays a role in both heritable and sporadic neoplasias.1
Cowden syndrome (CS [MIM 158350]) is a difﬁcult-to-rec-
ognize autosomal-dominant inherited cancer syndrome
characterized by benign and malignant breast, thyroid,
and endometrial neoplasias in addition to cutaneous ﬁnd-
ings and macrocephaly.2 Germline PTEN mutations have
been found in 85% of those with classic CS although
15% remain mutation negative despite extensive analyses
including the promoter and looking for large deletions and
rearrangements.3,4 Many more patients with features rem-
iniscent of CS, not meeting diagnostic criteria (National
Comprehensive Cancer Center Practice Guidelines
[NCCN]; Table S1 available online) and referred to as
CS-like, are evaluated by clinicians for CS and cancer risk.
CS is believed to be without genetic heterogeneity:5 to
date, only PTEN has been implicated in this syndrome.
However, there must exist other susceptibility genes for
CS and CS-like phenotypes, especially in the latter, which
appears to be a heterogeneous disease. We often obtain
clues to disease etiology by examining whether certain
CS/CS-like clinical features resemble those in other syn-
dromes, by examining downstream signaling, and/or byThe Amelooking at phenotype in murine models. In this situation,
the murine model only vaguely resembles human CS.1
One prominent feature in the mouse model is pheochro-
mocytoma, a neoplasia of the adrenal medulla, and its
closely related neural crest-derived paraganglioma (PGL).6
Pheochromocytoma and PGL are not known component
features of CS (NCCN; Table S1).
Succinate dehydrogenase (SDH) belongs to mitochon-
drial complex II, which participates in both the electron
transport chain and the Kreb’s cycle (reviewed by C.E.7).
SDH comprises four subunits, SDHA, B, C, and D, each of
which is encoded by autosomal genes on three different
chromosomes. Whereas homozygous/compound hetero-
zygous mutations in SDHA (MIM 600857) cause severe
neurological dysfunction and cardiomyopathy, heterozy-
gous germline mutations in SDHB-D (MIM 185470,
602413, 602690) cause a pheochromocytoma-PGL
syndrome.8 Approximately 1%–5% of carriers of SDHB or
SDHD mutations have been found to have renal cell carci-
noma or papillary thyroid cancer,9,10 which are also
features of CS. Fumarate hydratase (FH) is the enzyme im-
mediately downstream of SDH. Homozygous germline
mutations cause severe neurological dysfunction and
death whereas heterozygous mutations are associated
with hereditary leiomyomatosis and renal cell carcinoma
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mitochondrial caspases and HIF1 are downstream mole-
cules of the PTEN pathway.12,13 Therefore, we hypothe-
sized that SDHxmight represent susceptibility genes, other
than PTEN, for CS/CS-like syndromes.
Material and Methods
Patients
We utilized peripheral blood samples accrued from 375 CS and CS-
like individuals who were germline PTENmutation negative after
comprehensive mutation analysis that includes all nine coding
exons, ﬂanking intronic regions, and minimal promoter region
of PTEN and examination for large deletions and rearrangements
(Figure 1). Classic CS was diagnosed when the operational diag-
nostic criteria of the International Cowden Consortium were
met (Table S1).14 The diagnosis of CS-like was made when an indi-
vidual did notmeet any of the strict diagnostic criteria but had fea-
tures that were one or two criteria short of the operational diagnos-
tic criteria (Table S1). We utilized peripheral blood samples from
700 normal white populational controls of northern and western
European origin, which were anonymized prior to storage and
analysis. Informed consent was obtained for all subjects (CS/CS-
like individuals and controls) in accordance with procedures and
protocols approved by the respective Human Subjects Protection
Committee of each participating institution. All subjects, whether
CS/CS-like or controls, participated on a voluntary basis.
Mutation Analysis
Genomic DNAwas extracted from peripheral leukocytes, and PCR
ampliﬁcation and direct sequencing (ABI3730xl) of PTEN, SDHB,
SDHC, and SDHD were performed as previously reported by our
laboratory.15,16 It is important to note that all 700 controls had
the entire sequence of SDHB, SDHC, and SDHD sequenced and
no variants identiﬁed.
Figure 1. Experimental Design for SDH Mutation Testing
and Functional Analysis
Note PTEN gene testing encompasses intragenic PCR-based muta-
tion analysis, promoter, and large deletion analysis. From the
2270 PTENmutation-negative CS/CS-like individuals, themost prox-
imal (i.e., most recent) consecutive 375 PTEN mutation-negative
subjects were selected to proceed to MnSOD expression analysis.
It is these 375 subjects that represent the series for this SDH study.262 The American Journal of Human Genetics 83, 261–268, AugustCell Lines and Cell Culture
Human immortalized lymphoblast cell lines obtained from pa-
tients and controls were cultured in RPMI 1640 supplemented
with 20% fetal bovine serum (FBS). All cell lines were cultured at
37C with 5% CO2.
Protein Analysis
Whole-cell lystates were prepared with Mammalian Protein Ex-
traction Reagent (Pierce, Rockford, IL) supplemented with prote-
ase inhibitor cocktail (Sigma). Lysates were either separated by
SDS-PAGE and transferred to nitrocellulose or applied to nitrocel-
lulose with a dotblot apparatus (BioRad). The resulting blots were
then subjected to western blot analysis17 for either: SDHB (Ab-
Cam, USA), MnSOD (Upstate Biotechnology, Waltham, MA),
PTEN17 (Cascade Biosciences, Portland, OR) P-MAPK, MAPK,
AKT, P-AKT, or actin (Cell Signaling Co., Beverly, MA). For the
phosphorylation of MAPK, we utilized an antibody that recog-
nizes the activation phosphorylation of residues Thr187 and
Thr189 of the p44-MAPK and the equivalent phosphorylation in
p42-MAPK. For Akt phosphorylation, we utilized an antibody
that recognizes the activation phosphorylation of Ser473. Both
of these antibodies are traditionally utilized to monitor phosphor-
ylation, and thus activation, of these enzymes. Proteins were de-
tected with ECL substrate (Amersham Biosciences, Inc., Chicago,
IL) and autoradiography.
Confocal Microscopy
Images were collected with a Leica TCS SP2 AOBS confocal micro-
scope (Leica Micro-Systems, Heidelberg, GmbH) with a HCX Plan
Apo 63x/1.4 NA oil immersion lens. The cells were excited with
488 nm light from an Argon laser and emitted light was collected
between 500 and 550 nm. Collection parameters remained con-
stant for all samples. Quantitation of ROS was performed by stan-
dard FACS (HFE), with controls normalized to 1.
Statistical Analysis
The frequency of each of the established CS-speciﬁc component
carcinomas (breast and epithelial thyroid) and two of the strongly
suspected component carcinomas (renal cell and endometrial) in
SDHxmutation-positive individuals were compared to that in a co-
hort of 230 PTEN mutation-positive individuals with CS/CS-like
phenotypes. Both groups were ascertained by identical clinical cri-
teria, as noted in the ﬁrst section of Material andMethods. Fisher’s
2-tailed exact test was applied with signiﬁcance at p < 0.05.
Results
To address our hypothesis, we screened protein lysates from
375 PTENmutation-negative CS/CS-like individuals for in-
creased expression of manganese superoxide dismutase
(MnSOD) because the latter is a good indicator and ﬁrst
screen for general (complex I–VI, especially complex II or
V) mitochondrial dysfunction8,16,17 (Figure 1). Dot blot
analysis of these patients’ protein lysates and 18population
controls identiﬁed 74 (20%) PTEN mutation-negative pa-
tients with elevated MnSOD protein levels (Figures 1 and
2A). These 74 were subjected to SDHx mutation analysis
(Figure 1). Those that do not have elevated MnSOD levels
were not included because a pilot study of 40 CS/CS-like8, 2008
PTEN mutation-negative levels without elevated MnSOD
were shown not to harbor any SDHx mutations (A.P.,
K.M.Z., and C.E., unpublished data). Of the 74 with germ-
line elevations of MnSOD, 10 (13.5%; 95% conﬁdence in-
terval [CI] 7.3%–23.3%)were found tohave germlinemuta-
tions/variants in SDHB (n ¼ 3) or SDHD (n ¼ 7): Ala3Gly
and Ser163Pro (n ¼ 2) in SDHB and His145Asn (n ¼ 1),
His50Arg (n ¼ 2), and Gly12Ser (n ¼ 4) in SDHD (Figure 2;
Table 1). None of these SDH mutations were found in 700
normal controls (p < 0.001, Fisher’s 2-tailed exact test).
All three genes, SDHB/C/D, were sequenced in the controls
and no variants uncovered.
We then subjected the ﬁve different SDH mutations/
variants, identiﬁed in the 10 CS/CS-like individuals, for
functional analysis (Figure 2; Table 2). First, the increased
MnSOD protein levels noted on dot blot were conﬁrmed
by western blot (Table 2). Because it is known that SDH
dysfunction can result in increased production of reactive
oxygen species (ROS),18,19 we also tested the pathogenicity
of these different SDH mutations by direct measurements
of increased ROS levels by using carboxy-H2DCFDA and
confocal microscopy (Figure 1C; Table 2). SDHB Ser163Pro,
SDHD Gly12Ser, and His50Arg resulted in increased ROS
levels (Table 2). SDHB Ala3Gly and SDHD His145Asn, in
contrast, had normal ROS levels (Table 2).
PTEN is a tumor suppressor that downregulates the anti-
apoptotic/proproliferative AKT (protein kinase B)20 and
mitogen-activated kinase (MAPK) pathways.17 Therefore,
PTEN dysfunction is associated with activation of these
pathways, whose downstream readouts include phosphor-
ylated AKTandMAPK (p42/44ERKs) (Figure 2D). All 10 CS/
CS-like patients with the germline SDHB/D mutations
Figure 2. Genetic and Biochemical Analyses of CS/
CS-like Patients without Germline PTEN Mutations
Reveal a Subset with Germline SDH Mutations Result-
ing in Biochemical Dysfunction
(A) Dot blots to screen for increased MnSOD protein
levels. Boxed dots represent controls with low MnSOD
levels.
(B) Illustrative sequencing chromatograms of germline
heterozygous mutations of SDH genes identified in pa-
tients with CS/CS-like phenotypes (mutations as noted
above each chromatogram). The germline mutations/
variants are heterozygous manifested by overlapping
peaks (arrows).
(C) Increased ROS in peripheral lymphoblasts from an in-
dividual with germline SDHD His50Arg. Increased ROS
levels are measured by increased carboxy-H2DCFDA
staining as seen in cultured lymphoblast cells from the
patient with SDHD His50Arg mutation denoting 1.5-
fold higher ROS levels (middle) compared to a lympho-
blast cell line derived from a normal control individual
(left; p < 0.001, Student’s t test, 3 replicates). Finally,
a control lymphoblast cell line treated with tert-butyl
hydroperoxide for 90 min was used as a superpositive
control and suprainduced ROS expression is noted by
markedly increased carboxy-H2DCFDA staining (right).
(D) Protein expression of P-AKT and P-MAPK (P-ERK44/
42) in germline heterozygous PTEN mutation-positive
individuals. Note different mutations result in varying
activation of P-Akt and/or P-MAPK.
(E) Germline protein expression of PTEN, actin (loading
control), P-Akt, and P-MAPK (as labeled, from top to
bottom). Fold change values beneath the P-Akt and
P-MAPK blots represent the mean of normalized densito-
metrically obtained expressional levels of patient
sample(s) relative to controls. In other words, (Patient
P-Akt or P-MAPK intensity/corresponding patient actin
intensity)/(Control P-Akt or P-MAPK intensity/corre-
sponding control actin intensity). The ratio of control
P-Akt or P-MAPK intensity to control actin intensity
was normalized to 1.0. We have chosen to use this
type of quantitation (taking the ratio of the ratios)
because it results in the most conservative (i.e., under-
estimated) fold changes.The American Journal of Human Genetics 83, 261–268, August 8, 2008 263
Table 1. Genotype and Clinical Phenotype for PTEN Mutation-Negative Patients with Germline SDHB or SDHD
Mutations/Variants
Age/Sex
SDH Genotype Patient’s Clinical Features
Family HistoryGene Mutation Breast Thyroid Renal Uterus
41F SDHB Ala3Gly C L endometrial Cancer
29F SDHB Ser163Pro C B breast cancer, PTC
54F SDHB Ser163Pro C B breast cancer, PTC
69F SDHD Gly12Ser C C breast cancer, endometrial
62F SDHD Gly12Ser B B C L none
46F SDHD Gly12Ser C C L none
42F SDHD Gly12Ser C L none
56F SDHD His50Arg C C breast cancer
55M SDHD His50Arg C breast cancer, PTC
53F SDHD His145Asn C B C none
Abbreviations: C, carcinoma; B, benign pathology; L, uterine leiomyomas; PTC, family history of papillary thyroid carcinoma.showed activation of AKT and MAPK manifested by in-
creased phosphorylated AKT and MAPK in their germline,
when compared to normal controls (Figure 2D). Interest-
ingly, the SDHD His145Asn mutation and the SDHB
Ala3Gly mutation, which did not affect ROS, showed acti-
vation of the MAPK pathway and no or only mild activa-
tion of the AKT pathway (Table 2; Figure 2E).
Renal cell carcinoma was present in 2/10 (20%; 95% CI
5%–52%) CS/CS-like individuals with germline SDHmuta-
tions/variants (Table 1) compared to 4/230 (1.2%; 95% CI
0.5%–4.5%) with germline PTEN mutations (p ¼ 0.03,
Fisher’s 2-tailed exact test). Epithelial thyroid carcinoma
was found in 5 of 10 (50%; 95% CI 25%–76%) SDH muta-
tion-positive individuals (Table 1) compared to 15/206
(7.2%; 95% CI 4%–12%) with germline PTEN mutations
(p < 0.001). Interestingly, the histology of all the SDH-re-
lated thyroid cancers was papillary thyroid carcinoma com-
pared to only one of the 15 thyroid cancers in PTENmuta-
tion carriers (p< 0.001). Female breast cancer was found in
6 of 9 (66.7%; 95% CI 36%–88%) SDHx mutation-positive
women (Table 1) compared to 28% (95% CI 22%–34%) of
womenwith germline PTENmutations (p< 0.001). It is im-
portant to note that the frequencies of uterine endometrial
carcinomas and uterine leiomyomas in our women with264 The American Journal of Human Genetics 83, 261–268, AugustSDHx mutations were similar to those in women with
PTEN mutations (p > 0.05). One individual, the 55-year-
old man with germline SDHD His50Arg, was incidentally
found to have a unilateral pheochromocytoma.
Discussion
Our observations suggest that a subset of CS or CS-like in-
dividuals, without germline PTEN mutations, may be ac-
counted for by germline mutations or variants in either
the SDHB or SDHD, but not SDHC, genes. SDHB and
SDHD are the susceptibility genes for familial pheochro-
mocytoma-PGL syndrome.7 At least one of the ﬁve differ-
ent mutations found in the 10 CS/CS-like individuals,
SDHD His145Asn, has never been described before in indi-
viduals and families with pheochromocytoma and/or PGL
(SDHx Mutation Database). Because these mutations are
neither in dbSNP nor in our 700 control individuals, this
almost certainly is a pathogenic germline mutation.
His145 is also highly conserved through mouse, sheep,
and cow, arguing for the biological importance of this
amino acid residue. Functional analyses corroborate the
pathogenicity of this missense mutation. This mutationTable 2. Identified Germline SDHB or SDHD Mutations/Variants in PTEN Mutation-Negative CS/CS-like Individuals and Their
Functional Consequences
Mutation/Variant MnSODa ROS P-Akt Fold Change P-MAPK Fold Change
SDHB Ala3Gly increased normal 1.2 1.3
SDHB Ser163Pro increased increased 2.7 1.7
SDHD Gly12Ser increased increased 1.9 1.9
SDHD His50Arg increased increased 2.0 1.7
SDHD His145Asn increased normal 1.0 1.2
Fold change values represent the mean of normalized densitometrically obtained expressional levels of patient sample(s) relative to controls (where P-Akt/
actin or P-MAPK/actin is set to 1.0), i.e., a ratio of ratios.
ROS measurements were quantitated and normalized against controls (latter set at 1). The three mutations resulting in increased ROS had 1.5-fold over
controls.
See legend to Figure 2 for further details.
a Note that patients chosen for SDH analysis were selected for increased MnSOD protein expression.8, 2008
shows activation of the MAPK, but not AKT, pathway (Ta-
ble 2; Figures 2D and 2E), mimicking PTEN dysfunction via
the latter’s nuclear role and/or protein phosphatase activ-
ity.21 Thus, taken together, these genetic and functional
data represent strong evidence that SDHD His145Asn
mutation lends susceptibility to PTEN mutation-negative
CS/CS-like disorders.
The SDHB Ala3Gly variant is shown in dbSNP from the
Human Genome sequencing project, but no frequency is
noted. The latter usually means that it is an extremely
rare variant or it may be found in a nonwhite population.
Nonetheless, our germline Ala3Gly variant occurred in
a CS/CS-like individual who is white of Northern/Western
European ancestry, and this variant is absent in 700 nor-
mal chromosomes originating from 700 white controls
of the same ancestral background. More importantly,
Ala3Gly results in obvious activation of the MAPK path-
way andmild activation of the AKT pathway (Figure 2E; Ta-
ble 1). It would be important to note that dot blot analysis
of >700 normal controls showed that none of these con-
trol samples had increased MnSOD, increased P-MAPK,
or increased P-AKT (K.A.W., T.S., and C.E., unpublished
data). Thus, the functional data strongly suggest that
Ala3Gly is pathogenic and may function in a low-pene-
trance fashion in the CS/CS-like setting.
There are human genetic reports that both support and
refute SDHD Gly12Ser and His50Arg as pathogenic.22–24
These two variants have been reported to occur in 1.1%–
3% of Spanish population controls. His50Arg has been de-
scribed in 2%–3% of a French Canadian cohort as well.
SDHB Ser163Pro has been described in African-Americans
at a 2% frequency. However, none of our 700 control chro-
mosomes, originating from whites of Northern and West-
ern European ancestry, were found to harbor these three
variants (p < 0.001). None of our CS/CS-like patients nor
any of our controls are of Spanish, French Canadian, or Af-
rican ancestry. More importantly, we have shown that
these three variants do result in increased increased ROS
levels (Table 2; Figure 2). Of signiﬁcance to this report,
moreover, Ser163Pro, His50Arg, and Gly12Ser all result in
activated signaling down the AKT and MAPK pathways
(Figure 2E; Table 2), mimicking PTEN dysfunction al-
though none of these samples had PTEN alterations. Our
genetic and functional data, together with recent evidence
showing that most rare missense variants are deleterious,25
therefore, suggest that these three variants are pathogenic
at least in the context of our CS/CS-like individuals, and
might either be a lower penetrance allele or also signal
down other unknown pathways. Although we have pro-
vided genetic and strong functional evidence to show
that these three variants are pathogenic in the CS/CS-like
context, how do we explain the 1.1%–3% prevalence of
Gly12Ser and His50Arg in the Spanish or French-Canadian
populational controls and the 2% prevalence of Ser163Pro
in the black population? One hypothesis is that because
these are populational controls (in contrast to healthy
controls), these might be individuals who have CS/CS-likeThe Amephenotypes and have not been recognized given that these
syndromes are extremely difﬁcult to diagnose, and more
plausibly, these are individuals with partial phenotypes
(i.e., formes frustes), the latter of which are quite common
in the general population.
DNA from family members is not currently available for
testing segregation of the mutations with clinical pheno-
type within families, noting that four individuals do not
have any family history. However, maternal imprinting
of SDHD11 and decreased penetrance of SDHB11 muta-
tions, even in classic familial pheochromocytoma/
paraganglioma syndromes, may make this type of family
analysis, especially in this present setting, much less
informative. Importantly, we suggest that not only do
these mutations likely cause some sort of mitochondrial
dysfunction as evidenced by increased expression of
MnSOD and/or increased ROS, but they also show in-
creased signaling down the PI3K-AKT and/or MAPK path-
ways, the latter of which can occur with pathogenic
PTEN mutations as well. The reason why not all individ-
uals found to have increased MnSOD also have germline
SDHx mutations is because MnSOD levels are a broad
and general (and not necessarily speciﬁc) indication of mi-
tochondrial complex I-VI (electron transport/respiratory
chain) function.
We did not have access to the tissues or tumors for the
patients with germline SDH variants and mutations. How-
ever, because of the continuing lack of understanding of
SDH-related carcinogenesis, it may not be helpful to look
for loss of the remaining wild-type allele in tumors of these
current cases. In classic SDH-related pheochromocytoma/
paraganglioma syndromes, sometimes there is somatic
loss of the remaining wild-type allele accompanying the
germline mutation, but retention of the wild-type allele
is also observed.26,27 Even more puzzling is the well-docu-
mented maternally imprinted SDHD-related tumors. With
maternal imprinting, one would not expect to see loss of
the remaining allele but monoallelic expression of the
mutant (paternally transmitted) SDHD allele. In contrast,
paraganglioma from germline SDHD mutation-positive
individuals still show clear biallelic SDHD expression.26
The precise mechanism leading to neoplastic transfor-
mation in patients withmutations ofmitochondrial tumor
suppressors is not fully understood. One hypothesis sug-
gests that succinate, the substrate of SDH, functions as
a secondmessenger between themitochondria and cytosol
and inhibits the prolyl-hydroxylase enzymes, thus stabiliz-
ing HIF1.28 This inhibition could contribute to stabiliza-
tion of HIF and promote transcription of genes containing
hypoxic response elements.29 An alternative hypothesis is
that mutations in SDH result in increased ROS.18,19 This
metabolic stress results in genomic instability and accumu-
lation of HIF1.18 Additionally, increased ROS levels can in-
activate proteins, including PTEN, via protein oxidation.30
Because of these reports and our ﬁnding germline SDHB/D
mutations/variants in CS/CS-like individuals, we hypothe-
sized that at least a subset of germline PTEN mutationsrican Journal of Human Genetics 83, 261–268, August 8, 2008 265
may also lead to mitochondrial dysfunction. As proof of
principle, we found that 5 of 11 (45%) patients with germ-
line PTEN mutations actually had overexpression of
MnSOD protein in the absence of SDH mutation (A.P.
and C.E., unpublished data). Although our observations
and the existing literature suggest interesting signaling
crosstalk between the PTEN and mitochondrial signaling
pathways, it is also entirely possible that SDH-related
CS/CS-like phenotypes might be unrelated to the PTEN-
deﬁcient mechanism and may represent a previously
undescribed syndrome.
In summary, we have shown that a subset of patients
with CS or CS-like phenotypes likely has mitochondrial
dysfunction irrespective of PTEN mutation status, and
that this dysfunction can occur by different molecular
mechanisms (Figure 3). CS-associated SDHB or SDHD mu-
tations may be associated with activation of similar antia-
poptotic pathways as observed with germline PTEN muta-
tions, and that degree of mitochondrial dysfunction might
differentially affect the AKT and MAPK pathways. Thus,
failure of apoptosis regulation in patients, mediated by ei-
ther germline PTEN or SDH mutations, resulting in mito-
chondrial dysfunction, could be a unifying explanation
for tumorigenesis in these patients (Figure 3). Germline
SDH mutation carriers have signiﬁcantly higher frequen-
cies of breast, thyroid, and renal cell carcinomas compared
Figure 3. Proposed Model for the Final Common Pathway of
Putative Mitochondrial Dysfunction Resulting from Either
PTEN or SDHx Mutation in Cowden and Cowden-like Syndromes
A simplified version of the signaling pathways involved in tumor-
igenesis in the setting of dysfunctional PTEN or SDH (represented
by hatched colors). These pathways crosstalk, leading to the final
common outcome of tumor angiogenesis, cell proliferation, and in-
hibition of apoptosis. Note that one of the functions of SDH is the
conversion of succinate to fumarate as part of the Kreb’s tricarbox-
ylic acid cycle. SDH dysfunction will therefore lead to an accumu-
lation of succinate, which inhibits prolyl hydroxylases (PHD) and
subsequently leads to the stabilization of HIF-1a. The stabilization
of the latter also occurs a number of steps downstream of dysfunc-
tional PTEN signaling. It is interesting to note that activated Akt
(P-Akt) can increase ATP levels that result in increased ROS, pre-
sumably via mitochondrial dysfunctional signaling. This is postu-
lated to set up a double feedback loop linking both the PTEN and
SDH pathways.266 The American Journal of Human Genetics 83, 261–268, Augustto those with germline PTEN mutations (Table S1). It
would be important to note that germline SDH mutation
carriers have signiﬁcantly higher frequencies of breast, thy-
roid, and renal cell carcinomas compared to those without
germline PTEN and without SDH mutations as well (C.E.,
unpublished data). In this study, all SDH-related thyroid
cancers are papillary in contrast to PTEN-related epithelial
thyroid cancers where all but one are follicular histologies.
The frequencies of benign and malignant uterine disease
were virtually identical between those with germline
PTEN mutations and those with SDH mutations.
Our data have important implications for both patient
care and genetic counseling. Since 1997, the only suscepti-
bility gene for CS and individuals with some neoplasias
mimicking CS (CS-like) has been PTEN. Now, we suggest
SDH as a susceptibility gene for a subset of PTEN muta-
tion-negative patients with tumors reminiscent of those
component to CS. Because this study has analyzed in detail
only 10 SDH mutation-positive individuals with CS/CS-
like features, these data should be validated. Until then,
however, it would appear that SDH mutation-positive
CS/CS-like patients and their families may have signiﬁ-
cantly increased risks of carcinomas of the breast, thyroid
(especially papillary thyroid carcinoma), and kidney be-
yond those of PTEN-related CS. Germline PTEN muta-
tion-negative CS/CS-like individuals should be offered
SDH testing, especially in the setting of breast, papillary
thyroid, and/or renal carcinomas (Figure 4). Clinicians
may wish to consider annual renal ultrasounds and PGL-
type surveillance, beyond the NCCN practice guidelines
for PTEN hamartoma tumor syndrome, should an individ-
ual with tumors similar to those found in CS carry a germ-
line SDHx mutation or variant (Figure 4).
Supplemental Data
Supplemental data include one table and are available at http://
www.ajhg.org/.
Figure 4. Suggested Algorithm for Clinical PTEN and SDH
Testing for CS/CS-like Individuals
See text for details.8, 2008
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